Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy

BACKGROUND: We initiated this preclinical study in order to analyze the impact of sorafenib single treatment versus combination treatment in human colorectal cancer. METHODS: The effect of increasing sorafenib doses on proliferation, apoptosis, migration, and activation of signal cascades was analyz...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wehler, Thomas C., Hamdi, Swaantje, Maderer, Annett, Graf, Claudine, Gockel, Ines, Schmidtmann, Irene, Hainz, Michael, Berger, Martin R., Theobald, Matthias, Galle, Peter R., Moehler, Markus, Schimanski, Carl C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2012
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3587684/
https://ncbi.nlm.nih.gov/pubmed/22983756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00384-012-1551-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky